Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
A phase 1/2 trial of Pembrolizumab in head and neck squamous cell carcinoma and colorectal cancer, run by TiumBio Co., Ltd., now recruiting.
Overview
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05784688 by TiumBio Co., Ltd., with 140 participants planned, started 2023-03-10 and due to reach its primary completion in 2026-12. Interventions recorded: TU2218 + KEYTRUDA® (Pembrolizumab). Conditions listed: Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer. No results are recorded here; the registry entry is the source.
Setting
A Phase 1b/2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGFβR Serine/Threonine Kinase Inhibitor, Administered in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Phase
Phase 1/2
Sponsor
TiumBio Co., Ltd.
Registry
Enrolled
140